Other pathways also give rise to cancers due to Pparγ mutations with partial loss of function or chimeric mutations such as in colon cancer (205), prostate cancer (206), and thyroid tumors (207, 208) where Pparγ levels were associated with tumor grade and invasive ability. This evidence concerns the gene PPARG and prostate carcinoma.